2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12771
    O-desmethyl Mebeverine acid 586357-02-0 ≥99.0%
    O-desmethyl Mebeverine acid is a metabolite of Mebeverine, which is a musculotropic antispasmodic drug.
    O-desmethyl Mebeverine acid
  • HY-12813
    PDE10-IN-1 1516896-09-5 99.44%
    PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.
    PDE10-IN-1
  • HY-12850
    Dasotraline 675126-05-3 98%
    Dasotraline is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC50 values of 4, 6, and 11 nM, respectively.
    Dasotraline
  • HY-12959
    Repinotan 144980-29-0 98%
    Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with Ki values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects.
    Repinotan
  • HY-13047
    S-(+)-Mecamylamine hydrochloride 107596-30-5 ≥99.0%
    S-(+)-Mecamylamine (hydrochloride) is a neuronal nicotinic receptor modulator with antidepressant activity.
    S-(+)-Mecamylamine hydrochloride
  • HY-13796
    IPSU 1373765-19-5 ≥98.0%
    IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pKi of 7.85.
    IPSU
  • HY-14203
    (R)-Safinamide 174756-44-6 99.89%
    (R)-Safinamide, the enantiomer of safinamide (HY-70057), can inhibit MAO-B with an IC50 value of 0.45 μM.
    (R)-Safinamide
  • HY-14327
    FAUC 213 337972-47-1 99.86%
    FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. FAUC 213 has less activity on D2 and D3 receptors (Kis of 3.4 μM, 5.3 μM for hD2, hD3, respectively). FAUC 213 can cross the blood-brain barrier (BBB). FAUC 213 exhibits atypical antipsychotic characteristic.
    FAUC 213
  • HY-14328
    Sonepiprazole 170858-33-0 99.84%
    Sonepiprazole (PNU-101387G) is a selective D4 dopamine antagonist with Kis of 3.6, 10.1, 5147, and 7430 nM for rD4-Dopamine, hD4.2-Dopamine, rD2-Dopamine, and Histamine-H1 receptors, respectively.
    Sonepiprazole
  • HY-14419
    TCN238 125404-04-8 99.57%
    TCN238 is an orally bioavailable mGlu4 receptor positive allosteric modulator (PAM) with an EC50 of 1 μM.
    TCN238
  • HY-14441
    ML 10302 148868-55-7 98.95%
    ML 10302 is a potent agonist 5-HT4 receptor with Ki of 1.07 nM. 5-Hydroxytryptamine (5-HT4) receptor agonists stimulate gut motility through cholinergic pathways. ML10302 induces significant prokinesia both in the small bowel and colon through activation of cholinergic pathways. ML 10302 also has the potential for the research of neurology diseases.
    ML 10302
  • HY-14467
    GSK-269984A 892664-04-9 99.74%
    GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) antagonist with a pIC50 of 7.9.
    GSK-269984A
  • HY-14533
    K 01-162 677746-25-7 ≥98.0%
    K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease.
    K 01-162
  • HY-14559
    PRX-07034 hydrochloride 903580-39-2 98.97%
    PRX-07034 hydrochloride is a highly selective and potent 5-HT6 receptor antagonist with a Ki= 4-8 nM and an IC50 of 19 nM. PRX-07034 can be used for the research of enhancing working memory and cognitive flexibility.
    PRX-07034 hydrochloride
  • HY-14563
    VU10010 633283-39-3 98.70%
    VU10010 is a potent, highly selective and allosteric M4 mAChR potentiator with an EC50 of 400 nM. VU10010 binds to an allosteric site on M4 mAChR and increases affinity for acetylcholine and coupling to G proteins. VU10010 increases carbachol-induced depression of transmission at excitatory but not inhibitory synapses in the hippocampus.
    VU10010
  • HY-14848
    Naluzotan 740873-06-7 98.05%
    Naluzotan is a novel, potent, and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM, used for the treatment of anxiety and depression; Also a weak hERG K+ channel blocker, with IC50 of 3800 nM.
    Naluzotan
  • HY-15071
    YM90K 154164-30-4 98.32%
    YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions.
    YM90K
  • HY-15442
    Biphenylindanone A 866823-73-6 ≥99.0%
    Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders.
    Biphenylindanone A
  • HY-15856
    cis-(Z)-Flupentixol dihydrochloride 51529-01-2 98%
    cis-(Z)-Flupentixol dihydrochloride is a potent and selective DA D1/D2 receptor antagonist, with Ki values of 0.38 nM and 7 nM for D2 receptor and 5-HT2A, respectively.
    cis-(Z)-Flupentixol dihydrochloride
  • HY-16465
    IRL-1620 142569-99-1 99.69%
    IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM.
    IRL-1620
Cat. No. Product Name / Synonyms Application Reactivity